Log In Get Started
Press Releases March 27, 2026 08:50 AM

Trailblazer Merger Corporation I Announces Completion of Business Combination with Cyabra Strategy, Ltd.

Trailblazer Merger Corp. I Completes Business Combination with Cyabra Strategy, Ltd., Cancels Special Stockholders Meeting

By Hana Yamamoto TBMC
Trailblazer Merger Corporation I Announces Completion of Business Combination with Cyabra Strategy, Ltd.
TBMC

Trailblazer Merger Corp. I (TBMC) announced the completion of its previously announced business combination with Cyabra Strategy, Ltd. As a result, TBMC has canceled the special meeting of stockholders that had been scheduled for March 27, 2026.

Key Points

  • Trailblazer Merger Corp. I completed its business combination with Cyabra Strategy, Ltd.
  • The scheduled special meeting of TBMC stockholders was canceled following the merger completion.
  • The transaction involves a Special Purpose Acquisition Company (SPAC) and a target company focused on strategy and analytics.
  • Sectors impacted include SPACs, mergers and acquisitions, and technology/analytics markets.

Cancels  Special Meeting of Trailblazer Stockholders

NEW YORK , March 27, 2026 (GLOBE NEWSWIRE) -- Trailblazer Merger Corp. I (“TBMC”) announced today the closing of its previously announced business combination  with Cyabra Strategy, Ltd.

Accordingly, TBMC has canceled  its previously announced  special meeting of TBMC  stockholders that was scheduled to take place on March 27, 2026, at 10:00 a.m., Eastern Time.

TMBC Contact:
Yosef Eichorn
(646) 747-9618

[email protected]


Risks

  • Post-merger integration risks between Trailblazer Merger Corp. and Cyabra Strategy.
  • Market uncertainty about the combined company's future performance and operational synergy.
  • Potential volatility in SPAC-related securities affecting investor confidence.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026